BR0109570A - Compostos compreendendo uma parte especìfica de célula alvo e uma parte citotóxica, e uma parte mediadora capaz de reconhecer uma molécula especìfica de célula alvo e uma segunda parte citotóxica, molécula de ácido nucleico isolada, método para fabricar um composto, vetor para expressar em uma célula hospedeira, um composto, ou uma parte deste, célula hospedeira, composição farmacêutica, uso de um composto, e método para tratar um paciente tendo células alvo a serem destruìdas - Google Patents
Compostos compreendendo uma parte especìfica de célula alvo e uma parte citotóxica, e uma parte mediadora capaz de reconhecer uma molécula especìfica de célula alvo e uma segunda parte citotóxica, molécula de ácido nucleico isolada, método para fabricar um composto, vetor para expressar em uma célula hospedeira, um composto, ou uma parte deste, célula hospedeira, composição farmacêutica, uso de um composto, e método para tratar um paciente tendo células alvo a serem destruìdasInfo
- Publication number
- BR0109570A BR0109570A BR0109570-6A BR0109570A BR0109570A BR 0109570 A BR0109570 A BR 0109570A BR 0109570 A BR0109570 A BR 0109570A BR 0109570 A BR0109570 A BR 0109570A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- cytotoxic
- host
- cell specific
- target cell
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 10
- 231100000433 cytotoxic Toxicity 0.000 title abstract 7
- 230000001472 cytotoxic effect Effects 0.000 title abstract 7
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000011727 Caspases Human genes 0.000 abstract 4
- 108010076667 Caspases Proteins 0.000 abstract 4
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- FOIAQXXUVRINCI-LBAQZLPGSA-N (2S)-2-amino-6-[[4-[2-[bis(carboxymethyl)amino]-3-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propyl]phenyl]carbamothioylamino]hexanoic acid Chemical compound N[C@@H](CCCCNC(=S)Nc1ccc(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)cc1)C(O)=O FOIAQXXUVRINCI-LBAQZLPGSA-N 0.000 abstract 1
- 108090000397 Caspase 3 Proteins 0.000 abstract 1
- 102000004018 Caspase 6 Human genes 0.000 abstract 1
- 108090000425 Caspase 6 Proteins 0.000 abstract 1
- 102000004041 Caspase 7 Human genes 0.000 abstract 1
- 108090000567 Caspase 7 Proteins 0.000 abstract 1
- 102100029855 Caspase-3 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22056—Caspase-3 (3.4.22.56)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22059—Caspase-6 (3.4.22.59)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
"COMPOSTOS COMPREENDENDO UMA PARTE ESPECìFICA DE CéLULA ALVO E UMA PARTE CITOTóXICA, E UMA PARTE MEDIADORA CAPAZ DE RECONHECER UMA MOLéCULA ESPECìFICA DE CéLULA ALVO E UMA SEGUNDA PARTE CITOTóXICA, MOLéCULA DE áCIDO NUCLEICO ISOLADA, MéTODO PARA FABRICAR UM COMPOSTO, VETOR PARA EXPRESSAR EM UMA CéLULA HOSPEDEIRA, UM COMPOSTO, OU UMA PARTE DESTE, CéLULA HOSPEDEIRA, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E MéTODO PARA TRATAR UM PACIENTE TENDO CéLULAS ALVO A SEREM DESTRUìDAS". Um composto que compreende uma parte específica de célula alvo e uma parte citotóxica, caracterizado em que a parte citotóxica do composto é uma caspase constitutivamente ativa ou tem substancialmente a mesma atividade indutora de apoptose como as ditas caspases. Alternativamente, a invenção fornece um composto que compreende uma parte mediadora e uma parte citotóxica, caracterizado em que a parte citotóxica do composto é uma caspase constitutivamente ativa ou tem substancialmente a mesma atividade indutora de apoptose como as ditas caspases. Preferivelmente a parte citotóxica dos compostos da invenção é uma caspase 3, caspase 6 ou caspase 7 constitutivamente ativas. A invenção ainda fornece ácidos nucleicos que codificam os compostos da invenção e os usos de tais compostos na medicina, por exemplo, no tratamento do câncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0007343A GB2360771A (en) | 2000-03-28 | 2000-03-28 | Compounds for targeting |
| PCT/GB2001/001354 WO2001072336A1 (en) | 2000-03-28 | 2001-03-28 | Compounds for targeting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0109570A true BR0109570A (pt) | 2003-01-28 |
Family
ID=9888460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0109570-6A BR0109570A (pt) | 2000-03-28 | 2001-03-28 | Compostos compreendendo uma parte especìfica de célula alvo e uma parte citotóxica, e uma parte mediadora capaz de reconhecer uma molécula especìfica de célula alvo e uma segunda parte citotóxica, molécula de ácido nucleico isolada, método para fabricar um composto, vetor para expressar em uma célula hospedeira, um composto, ou uma parte deste, célula hospedeira, composição farmacêutica, uso de um composto, e método para tratar um paciente tendo células alvo a serem destruìdas |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1267940B1 (pt) |
| JP (1) | JP2003528156A (pt) |
| KR (1) | KR20030022782A (pt) |
| CN (1) | CN1420789A (pt) |
| AT (1) | ATE240122T1 (pt) |
| AU (1) | AU4850101A (pt) |
| BR (1) | BR0109570A (pt) |
| CA (1) | CA2402453A1 (pt) |
| DE (1) | DE60100274T2 (pt) |
| DK (1) | DK1267940T3 (pt) |
| ES (1) | ES2202287T3 (pt) |
| GB (2) | GB2360771A (pt) |
| IL (1) | IL151675A0 (pt) |
| MX (1) | MXPA02009376A (pt) |
| NO (1) | NO20024587L (pt) |
| NZ (1) | NZ521289A (pt) |
| PL (1) | PL358482A1 (pt) |
| PT (1) | PT1267940E (pt) |
| RU (1) | RU2002128746A (pt) |
| WO (1) | WO2001072336A1 (pt) |
| ZA (1) | ZA200207157B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU783679B2 (en) * | 2000-02-24 | 2005-11-24 | Genentech Inc. | Caspase activated prodrugs therapy |
| CA2869088A1 (en) * | 2002-02-07 | 2003-08-14 | Massachusetts Institute Of Technology | Anti-pathogen treatments |
| CA2800173C (en) * | 2010-05-21 | 2019-05-14 | Ulrik Nielsen | Bi-specific fusion proteins |
| KR20220019660A (ko) * | 2019-04-02 | 2022-02-17 | 이뮨튠 비.브이. | 면역-자극성 조성물 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019553D0 (en) * | 1990-09-07 | 1990-10-24 | Unilever Plc | Specific binding agents |
| EP1149913A1 (en) * | 1990-11-09 | 2001-10-31 | GILLIES, Stephen D. | Cytokine immunoconjugates |
| GB9120467D0 (en) * | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| WO1994011508A2 (en) * | 1992-11-13 | 1994-05-26 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
| GB2289679B (en) * | 1993-01-15 | 1997-02-05 | Imp Cancer Res Tech | Compounds comprising a target cell-specific portion and a portion which has DNA endonucleolytic activity, and uses thereof |
| US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| US6428788B1 (en) * | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
| AU1818299A (en) * | 1997-12-10 | 1999-06-28 | Washington University | Anti-pathogen system and methods of use thereof |
| US6379950B1 (en) * | 1998-01-09 | 2002-04-30 | Thomas Jefferson University | Recombinant, active caspases and uses thereof |
| US6645490B2 (en) * | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
-
2000
- 2000-03-28 GB GB0007343A patent/GB2360771A/en not_active Withdrawn
-
2001
- 2001-03-28 AU AU48501/01A patent/AU4850101A/en not_active Abandoned
- 2001-03-28 PT PT01921524T patent/PT1267940E/pt unknown
- 2001-03-28 GB GB0107725A patent/GB2360772B/en not_active Expired - Fee Related
- 2001-03-28 NZ NZ521289A patent/NZ521289A/en unknown
- 2001-03-28 AT AT01921524T patent/ATE240122T1/de not_active IP Right Cessation
- 2001-03-28 DE DE60100274T patent/DE60100274T2/de not_active Expired - Fee Related
- 2001-03-28 KR KR1020027012649A patent/KR20030022782A/ko not_active Application Discontinuation
- 2001-03-28 WO PCT/GB2001/001354 patent/WO2001072336A1/en active IP Right Grant
- 2001-03-28 MX MXPA02009376A patent/MXPA02009376A/es unknown
- 2001-03-28 EP EP01921524A patent/EP1267940B1/en not_active Expired - Lifetime
- 2001-03-28 CA CA002402453A patent/CA2402453A1/en not_active Abandoned
- 2001-03-28 CN CN01807423A patent/CN1420789A/zh active Pending
- 2001-03-28 IL IL15167501A patent/IL151675A0/xx unknown
- 2001-03-28 BR BR0109570-6A patent/BR0109570A/pt not_active IP Right Cessation
- 2001-03-28 PL PL01358482A patent/PL358482A1/xx not_active Application Discontinuation
- 2001-03-28 ES ES01921524T patent/ES2202287T3/es not_active Expired - Lifetime
- 2001-03-28 DK DK01921524T patent/DK1267940T3/da active
- 2001-03-28 RU RU2002128746/15A patent/RU2002128746A/ru not_active Application Discontinuation
- 2001-03-28 JP JP2001570297A patent/JP2003528156A/ja not_active Withdrawn
-
2002
- 2002-09-05 ZA ZA200207157A patent/ZA200207157B/en unknown
- 2002-09-25 NO NO20024587A patent/NO20024587L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB0007343D0 (en) | 2000-05-17 |
| EP1267940A1 (en) | 2003-01-02 |
| RU2002128746A (ru) | 2004-03-27 |
| KR20030022782A (ko) | 2003-03-17 |
| ZA200207157B (en) | 2003-12-05 |
| NZ521289A (en) | 2004-04-30 |
| EP1267940B1 (en) | 2003-05-14 |
| NO20024587L (no) | 2002-11-25 |
| GB2360771A (en) | 2001-10-03 |
| CA2402453A1 (en) | 2001-10-04 |
| WO2001072336A1 (en) | 2001-10-04 |
| GB2360772B (en) | 2002-05-22 |
| PL358482A1 (en) | 2004-08-09 |
| GB2360772A (en) | 2001-10-03 |
| AU4850101A (en) | 2001-10-08 |
| MXPA02009376A (es) | 2004-05-14 |
| IL151675A0 (en) | 2003-04-10 |
| JP2003528156A (ja) | 2003-09-24 |
| GB0107725D0 (en) | 2001-05-16 |
| DK1267940T3 (da) | 2003-09-08 |
| PT1267940E (pt) | 2003-09-30 |
| DE60100274T2 (de) | 2004-04-01 |
| ES2202287T3 (es) | 2004-04-01 |
| CN1420789A (zh) | 2003-05-28 |
| NO20024587D0 (no) | 2002-09-25 |
| ATE240122T1 (de) | 2003-05-15 |
| DE60100274D1 (de) | 2003-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU94045281A (ru) | Иммуноконъюгаты, способ получения иммуноконъюгата, фармацевтическая композиция, применение иммуноконъюгата | |
| WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| WO2001072962A3 (en) | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
| PT1311285E (pt) | Composicao farmaceutica liquida contendo um derivado de eritropoietina | |
| MXPA04000920A (es) | Derivados de aminoisoxazol activos como inhibidores de la cinasa. | |
| ZA958444B (en) | Biological active proteins | |
| DK0910647T3 (da) | Human DNase i hyperaktive varianter | |
| BRPI0411112A (pt) | proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga | |
| NO20054842L (no) | Kjemiske forbindelser | |
| WO2001034802A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| HUP0400231A2 (hu) | Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények | |
| WO2001023421A3 (en) | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease | |
| KR20190110156A (ko) | 세타-디펜신들로 염증성 프로테아제들의 차단 | |
| BR9911349A (pt) | Genes para a biossìntese de epotilonas | |
| EA200300934A1 (ru) | Агенты и способы, предназначенные для лечения опухолевых заболеваний | |
| BR0210994A (pt) | Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e células | |
| BRPI0409554A (pt) | peptacorpo de fusão isolado e recombinante, seqüência de dna, vetor, célula hospedeira, composição farmacêutica e seu uso, kits, método para a produção do peptacorpo de fusão e seqüência de intensificador | |
| BR0109570A (pt) | Compostos compreendendo uma parte especìfica de célula alvo e uma parte citotóxica, e uma parte mediadora capaz de reconhecer uma molécula especìfica de célula alvo e uma segunda parte citotóxica, molécula de ácido nucleico isolada, método para fabricar um composto, vetor para expressar em uma célula hospedeira, um composto, ou uma parte deste, célula hospedeira, composição farmacêutica, uso de um composto, e método para tratar um paciente tendo células alvo a serem destruìdas | |
| DE60330914D1 (de) | Arzneimittel mit shikonin als wirkstoff | |
| WO2003093419A3 (en) | Preventing secondary lymphedema with vegf-d dna | |
| DE69814691D1 (de) | Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten | |
| EA199901061A1 (ru) | Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии | |
| AR014884A1 (es) | Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica | |
| WO2002045657A3 (en) | Ovarian tumor antigen and methods of use therefor | |
| AU2001249267A1 (en) | Methods and compositions for elucidating protein expression profiles in cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: C12N 9/64 (2006.01), C07K 16/28 (2006.01), C07K 16 |